Incyte Corporation (NASDAQ:INCY) is a prominent entity in the Medical - Biomedical and Genetics industry. The company is known for its innovative treatments, particularly in the field of oncology. Incyte's flagship product, Jakafi, is a leading treatment for blood cancer, contributing significantly to the company's revenue. The company competes with other major players in the pharmaceutical industry, striving to maintain its position through continuous research and development.
On October 29, 2025, RBC Capital set a price target of $84 for Incyte, while the stock was trading at $91.65. This target suggests a potential downside of approximately -8.35%. Despite this, Incyte's recent financial performance has been strong. In the third quarter of 2025, the company reported earnings of $2.26 per share, surpassing the Zacks Consensus Estimate of $1.66 per share. This represents a significant earnings surprise of 36.14%.
Incyte's revenue for the third quarter of 2025 was $1.37 billion, exceeding the Zacks Consensus Estimate by 8.71%. This is an increase from the $1.14 billion reported in the same period last year. The company has consistently outperformed revenue expectations over the past four quarters. The strong demand for Jakafi has been a key driver of this growth, leading Incyte to raise its annual sales forecast for the drug.
The stock for INCY is currently priced at $89.66, reflecting a decrease of 2.17% with a change of $1.99. Today, the stock has fluctuated between a low of $88.34 and a high of $94.42. Over the past year, the stock has reached a high of $94.42 and a low of $53.56. The company has a market capitalization of approximately $17.5 billion. The trading volume for the day is 597,177 shares.
